AZ-保密协议-可参考保密协议模板

　 阿斯利康投资（中国）有限公司AstraZeneca Investment (China) Co., Ltd.ABC贸易有限公司保密协议CONFIDENTIALITY AGREEMENT1.定义和解释/DEFINITIONS AND INTERPRETATION42.生效时间和期限/COMMENCEMENT AND TERM83.保密规定/CONFIDENTIALITY94.陈述与保证/REPRESENTATIONS AND WARRANTIES145.无许可使用或信赖/NO LICENCE OR RELIANCE146.继续有效/SURVIVAL157.转让和关联方/ASSIGNMENT AND AFFILIATES158.反腐败法/ANTI-CORRUPTION LAWS159.一般规定/GENERAL PROVISIONS16本协议双方/PARTIES(1)阿斯利康投资（中国）有限公司，一家根据中国法律在中国注册成立的公司，注册地址：中国上海市亮景路199号（“阿斯利康”）；AstraZeneca Investment (China) Co., Ltd., a company incorporated in and according to the laws of the People’s Republic of China with the registered address at No.199 LiangjingRoad, shanghai, China ("AstraZeneca"); and (2)ABC有限公司，一家在中国注册成立的公司，注册地址为（“ABC”）。[ABC Co., Ltd] a company incorporated in Chinawith its registered office at (the "Organisation")引言/RECITALS(A)双方为发展其之间有关XXXX技术、领域相关合作的拟议业务关系，有意向对方披露保密信息（“业务目的”）。Each Party wishes to disclose Confidential Information to the other in relation to the development of a proposed business relationship between them concerning collaboration in XXX area (the "Business Purpose"). (B)双方有意确保接收方对披露方提供的保密信息予以保密。Each Party wishes to ensure that the Receiving Party maintains the confidentiality of the Disclosing Party’s Confidential Information.条款正文/OPERATIVE PROVISIONS鉴于本协议中双方的义务以及其他有效对价，且各方在此确认收到该等允诺、对价及其充分性，各方达成以下有法律约束力的协议：NOW THEREFORE, in consideration of the mutual covenants contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows:定义和解释/DEFINITIONS AND INTERPRETATION术语定义/Defined Terms除非本协议另有特别规定，否则下列术语应具有以下含义：Unless otherwise specifically provided in this Agreement, the following terms shall have the following meanings:“关联方”，就法律实体而言，指不时控制该法律实体、受该法律实体不时控制或与该法律实体不时受共同控制的任何其他人。"Affiliate" means, with respect to a Person, any Person that Controls, is Controlled by or is under common Control with such Person from time to time.“适用法律和条例”指所有国家、地方、外国或省级机构的法律、规则和条例、任何监管机构的任何指南、指引和监管要求，以及任何适用于本协议所拟议或根据本协议所从事之活动的不时有效的行业行为守则。"Applicable Laws and Regulations" means all national, foreign or provincial laws, rules, regulations, as well any guidance, guidelines and requirements of any Regulatory Authorities and any industry codes of practice in effect from time to time applicable to the activities performed under or contemplated by this Agreement.“行为守则”指阿斯利康不时生效的行为守则。可在以下网址获取有关该守则的信息：/Responsibility/Code-policies-standards/Code-of-Conduct"Code of Conduct" means the AstraZeneca Code of Conduct available at /Responsibility/Code-policies-standards/Code-of-Conduct, as in force from time to time.“保密信息”指披露方的商业秘密及所有其他专有及/或保密性质的信息，包括:"Confidential Information" means all information constituting a trade secret and all other information of a proprietary and/or confidential nature belonging to the Disclosing Party, including:财务或业务信息、业务计划、规划或战略、商业惯例和商业关系、公司政策、程序、惯例或程序、制度、运营方法或营销计划；financial or business information, business plans, projections or strategies, business practices and relationships, corporate policies, procedures, practices or processes, systems, methods of operation or marketing plans; 研究、开发或其他调查活动；research, development or other investigative activities; 监管惯例、程序或政策；regulatory practices, procedures or policies; 产品信息、规格、配方、成分、定价政策、营销计划、产品费用或促销活动；product information, specifications, formulas, ingredients, pricing policies, marketing plans, product costs or promotional activities; 有关客户、供应商或员工方面的信息或协议；customer, supplier or employee information or agreements; 医学、科学信息或数据，或其他技术信息或数据；medical, scientific or other technical information or data; 公司订立的协议、战略、商业或许可协议，或其他协议；corporate, strategic, commercial, license or other agreements;发明、创新、改进、专有技术、生产方法、使用方法、商业秘密，或其他专有信息；inventions, innovations, improvements, know-how, methods of manufacture, use, trade secrets or other proprietary information;任何可能被合理商业人士视为具有保密性质的、与下列各项有关的信息any information that would be regarded as confidential by a reasonable business person relating to: 披露方的业务、事务、顾客、客户、供应商、计划、发明或市场机会；the business, affairs, customers, clients, suppliers, plans, intentions, or market opportunities of the Disclosing Party; 披露方的运营、程序、产品信息、专有技术、设计、商业秘密或软件；及the operations, processes, product information, know-how, designs, trade secrets or software of the Disclosing Party; and正在就业务目的进行讨论和谈判的事实，以及该等讨论和谈判的进展状况。the fact that discussions and negotiations are taking place concerning the Business Purpose and the status of those discussions and negotiations; 以上各项所述信息由披露方以口头、书面形式或以论证形式披露给接收方，或包含在其他形式（包括数据、文件、图案、胶片、计算机可读媒介、磁带、手册、规格说明、流程图、程序列表及数据文件打印资料等）媒介中。因任何保密信息产生的或源自保密信息的任何信息，以及包含在任何媒介（包括接收方或其代表提供的任何材料）中的任何信息，亦应视为披露方的保密信息。which is disclosed to the Receiving Party whether orally, in documentary form, by demonstration or otherwise and contained in any form whatsoever (including data, documents, drawings, films, computer readable media, magnetic tapes, manuals, specifications, flowcharts, program listings and data file printouts). Any information arising out of or deriving from any Confidential Information and contained in any form whatsoever (including any such materials produced by or on behalf of the Receiving Party) shall also be deemed to be Confidential Information of the Disclosing Party.“控制”指（a）通过拥有有表决权股份，或依据与表决权或公司治理有关的合约，或以其他方式，直接或间接有权对某法律实体的管理或政策发出指示；或（b）直接或间接拥有该法律实体发行的有表决权股份的50%以上，或直接或间接拥有该法律实体其他所有者权益的50%以上。“被控制”应具有相应的含义。"Control" means (a) to possess, directly or indirectly, the power to direct the management or policies of a Person, whether through ownership of voting securities or by contract relating to voting rights or corporate governance or otherwise (b) to own, directly or indirectly, more than fifty percent (50%) of the outstanding voting securities or other ownership interest of such Person and "Controlled" shall have a corresponding meaning.“披露方”指在相关情况下直接或间接披露或被代表披露保密信息的一方（如果阿斯利康为披露方，则阿斯利康的关联方亦为披露方）。"Disclosing Party" means the Person which discloses directly or indirectly Confidential Information (including in the case of AstraZeneca, any Affiliate of AstraZeneca) in a particular instance or on whose behalf Confidential Information is furnished.“生效日”指签约日。"Effective Date" meansthe date of execution of this Agreement.“双方”指阿斯利康和ABC；“一方”指阿斯利康或ABC。"Parties" means AstraZeneca and ITSC and "Party" shall mean either AstraZeneca or ITSC.“被许可的接受方”指根据本协议第3.2（C）条及本协议中的其他规定，在接收方获得适当许可后，可从接收方受让保密信息的法律实体。"Permitted Recipient" means a Person to whom the Receiving Party is properly permitted to transfer Confidential Information in accordance with clause 3.2(C) and otherwise in accordance with this Agreement.“法律实体”指个人、独资企业、合伙企业、有限合伙企业、有限责任合伙企业、公司、有限责任公司、商业信托、股份公司、信托、法人型社团、合营企业或类似实体或组织，包括监管机构。"Person" means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a Regulatory Authority.“接收方”指直接或间接从披露方接收保密信息的一方。"Receiving Party" means the Party receiving Confidential Information, whether directly or indirectly from a Disclosing Party.“监管机构”指任何国家、地方、外国或省级的法院或政府机关，包括前述各项的任何行政区，以及任何部门、委员会、局办、机关或其他政府监管或行政机关或机构，还包括行使前述各项职能的任何准政府机构。"Regulatory Authority" means any court or government body, whether national, local, foreign or provincial, including any political subdivision thereof, including any department, commission, board, bureau, agency, or other regulatory or administrative governmental authority or instrumentality, and further including any quasi-governmental Person exercising the functions of any of these.“期限”指本协议第2条规定的期限。"Term" means the term of this Agreement as set out in clause 2.解释/Interpretation除非文意另有所指：Unless the context requires otherwise:凡提及本协议之处，均指经不时修订的本协议；references to this Agreement are to this Agreement as it is from time to time amended; 标题仅为行文方便而设，不影响对本协议的解释；headings are for convenience only and shall not affect interpretation;凡提及条款之处，均指本协议的主体部分；references to clauses are to clauses in the main body of this Agreement;凡提及的单数形式均包括复数形式，反之亦然；凡提及的某个性别均包括所有其他性别；references to the singular include the plural and vice versa, and references to one gender include all genders;凡以“包括”、“尤其是”等词语或任何类似词语引导的任何短语，均应解释为具有说明意义，并不限制列于其前的任何词语的含义；any phrase introduced by the expressions "including", "include", "in particular" or any similar expression shall be construed as illustrative and shall not limit the sense of the words preceding those terms;凡提及任何法律：reference to any law:均应视为包括该法项下的任何细则、许可、法定文件、规则、条例、命令、通知、指示、同意或许可；且shall be deemed to include any bye-laws, licences, statutory instruments, rules, regulations, orders, notices, directions, consents or permissions made under that law; and均应解释为提及该等法律在任何时候的替代法、重新立法、修订立法或合并立法（无论是否修改该法）；shall be construed as referring to any law which replaces, re-enacts, amends or consolidates such law (with or without modification) at any time;凡提及“书面”形式，均包括任何以清晰、永久形式复制词语的方式，但不包括可在可视显示器或其他类似装置等屏幕上显示文字的书面形。references to "writing" or "written" include any modes of reproducing words in a legible and non transitory form but do not include writing on the screen of a visual display unit or other similar device.生效时间和期限/COMMENCEMENT AND TERM本协议在生效日生效。This Agreement shall be effective as of the Effective Date.本协议有效期为5年。The term of this Agreement is 5 years. 保密规定/CONFIDENTIALITY每一方均可向另一方披露与业务目的有关的保密信息。Each Party may disclose Confidential Information to the other in connection with the Business Purpose.就一方以接收方身份接收的保密信息而言，接收方做出以下承诺：Each Party undertakes as follows in respect of Confidential Information for which it is the Receiving Party:对保密信息予以保密；to treat the Confidential Information as confidential;不得将保密信息用于业务目的以外的任何其他目的；not to use the Confidential Information for any purpose other than the Business Purpose;除以下法律实体外，不得向任何其他人直接或间接公布、提供或以其他方式传达或披露保密信息的任何部分、其存在的事实或性质：not to publish, make available or otherwise communicate or disclose, directly or indirectly, any part of the Confidential Information or its existence or nature to any Person except:经特别告知披露方并获得其事先书面同意后的指定人士；to specified persons with the Disclosing Party’s specific informed prior written consent;接收方有合理理由需要知悉和使用保密信息，以使用于相关业务目的的高管、员工、董事、[顾问、代理人、代表、承包商或分承包商]；to those officers, employees, directors, [consultants, agents, representatives, contractors or subcontractors] of the Receiving Party who have a reasonable need to know and use the Confidential Information for the Business Purpose;接收方的审计师和专业顾问，以及因涉及接收方的业务（包括与一方或其任何关联方的股票交易的原因）在法律上有权或有义务获取或知悉保密信息的任何其他法律实体或机构；或to the Receiving Party’s auditors and professional advisers and any other Persons or bodies having a legal right or duty to have access to or knowledge of the Confidential Information in connection with the business of the Receiving Party including in relation to any stock exchange on which shares in a Party or any Affiliate of that Party are traded; or接收方为实现业务目的聘请的、并在披露前已获得披露方明示书面授权接收保密信息的任何第三方；any third parties engaged by the Receiving Party in order to achieve the Business Purpose and who have been expressly authorised in writing by the Disclosing Party to receive the Confidential Information prior to disclosure,但是在接收方为阿斯利康时，第3.2（C）条（ii）项、（iii）项和（iv）项中的“接收方”，应包括阿斯利康的关联方，且：provided that where the Receiving Party is AstraZeneca, then “Receiving Party” in clauses 3.2(C)(ii) and (iii) and (iv) shall include AstraZeneca’s Affiliates and provided always that:接收方在披露前，应向第3.2（C）条所述法律实体和机构告知保密信息的保密性质以及接收方就保密信息应承担的义务；prior to such disclosure, the Receiving Party has informed each of the Persons and bodies mentioned in clause 3.2(C) of the confidential nature of the Confidential Information and the obligations of the Receiving Party in respect thereof;接收方在披露前，应确保第3.2（C）条所述每一法律实体（不限于在法律上有权获取保密信息的法律实体）书面同意，其应与接收方同样受接收方根据本协议应承担的保密义务之约束；和prior to such disclosure, the Receiving Party has ensured that each of the Persons mentioned in clause 3.2(C) above (more than those with a legal right to access the Confidential Information) have agreed in writing to be bound by the same obligations of confidentiality as apply to the Receiving Party under this Agreement; and接收方应确保第3.2（C）条所述法律实体遵守第3.2条所述保密义务；和the Receiving Party ensures that the Persons mentioned in clause 3.1(C) above comply with such obligations of confidentiality as described in clause 3.1(C)(iii); and采取并维持充分的安全措施，防止保密信息被他人擅自获取、使用或滥用，且措施的严密程度不得低于接收方保护其自身保密信息时采取的安全措施。to effect and maintain adequate security measures to safeguard the Confidential Information from unauthorised access, use and misappropriation provided that such measures shall be no less stringent than those taken by the Receiving Party in respect of its own confidential information.若接收方能够同时以书面方式证明相关保密信息具有以下情形，第3.2条所述保密义务不适用于任何保密信息：The obligations of confidentiality set out in clause 3.2 shall not apply to any Confidential Information where the Receiving Party can prove by contemporaneous written evidence that the Confidential Information concerned:该等保密信息在披露方向接收方披露时已进入公有领域；was in the public domain at the time of disclosure by the Disclosing Party;该等保密信息在披露方向接收方披露后，并非因接收方、其关联方、被许可的接受方或前述各项的高管、董事、顾问、代理人、代表、承包商或分承包商的过失、恶意行为、故意不端行为或违反本协议项下任何义务或保密义务等原因进入部分公有领域；became a part of the public domain subsequent to disclosure by the Disclosing Party otherwise than as a result of the negligence, bad faith, wilful misconduct or breach of any obligation under this Agreement or of confidentiality by the Receiving Party or its Affiliates or Permitted Recipients or its/their officers, employees, directors, consultants, agents, representatives, contractors or subcontractors;该等保密信息在披露方或其代表接收或获取之日，已由接收方所有并由其在无需承担保密义务的情况下自由处置；was already in the possession of the Receiving Party and at its free disposal under no obligation of confidentiality at the date it was disclosed by or obtained from or on behalf of the Disclosing Party; 该等保密信息由就该等保密信息对任何法律实体不负有保密义务的第三方，以非保密方式向接收方披露；was lawfully disclosed to the Receiving Partyon a non-confidential basis by a third party who is not under an obligation of confidentiality to any Person in respect of that Confidential Information; 该等保密信息必须根据适用法律或条例，或有管辖权的法院或其他监管机构的命令依法披露；但是，在法律允许接收方按前述方式行事时，接收方应在披露前向披露方发出充分的通知，使披露方就该等保密信息寻求签发保护令或采取类似保护措施；或must be disclosed in compliance with Applicable Laws or Regulations or by order of a court or other Regulatory Authority of competent jurisdiction, provided that, to the extent that it is lawfully permitted to do so, the Receiving Partygives the Disclosing Party sufficient notice prior to such disclosure to enable the Disclosing Party to seek a protective order or similar protective measures with respect to such Confidential Information; or该等保密信息由接收方独立开发，且开发时未获取、参考或使用披露方的保密信息。has been independently developed by the Receiving Party without access to, reference to or use of the Confidential Information.所有保密信息应该且将持续属于披露方的专有财产。保密信息的所有复制件均应属于披露方的专有财产，并包含原件所示著作权及其他专有权利、通知或图例。All Confidential Information shall be and will remain the exclusive property of the Disclosing. Any copies of the Confidential Information shall become the Disclosing Party’s exclusive property and shall contain such copyright and other proprietary rights, notices or legends as appear on the original.阿斯利康可向其关联方披露从ABC接收的保密信息，用于与业务目的有关的用途，但阿斯利康应负责确保其关联方遵守本协议的规定。ABC确认，阿斯利康披露的保密信息可能与阿斯利康及其所有或任何关联方有关，因此，阿斯利康或其任何关联方均可强制要求ABC履行其在本协议项下的义务。AstraZeneca may disclose Confidential Information received from ITSC to its Affiliates for use in connection with the Business Purpose and AstraZeneca shall be responsible for observance of the provisions of this Agreement by such Affiliates. ITSC acknowledges that Confidential Information disclosed by AstraZeneca may relate to AstraZeneca and all or any of its Affiliates as a whole and accordingly, AstraZeneca or any of its Affiliates may enforce all of the obligations of ITSC under this Agreement.经披露方随时要求终止本协议之时，每一接收方应：On request of the Disclosing Party at any time and upon termination of this Agreement, each Receiving Party shall:立即向披露方交付披露方提供的、可能包含或含有保密信息的所有材料及该等材料的任何复制件，或应披露方的要求，销毁或删除接收方持有的任何保密信息，包括接收方编制的任何材料和文件中所含的任何保密信息，或任何记忆存储装置记录的任何保密信息；及promptly deliver to the Disclosing Party all materials supplied by the Disclosing Party which contain or incorporate such Confidential Information, together with any copies thereof or, at the Disclosing Party's option, destroy or erase any Confidential Information held by the Receiving Party including any Confidential Information contained in any materials and documents prepared by the Receiving Party or recorded in any memory device; and在履行第3.6（A）条项下义务后的十四（14）日内，以书面方式向披露方证实其已充分履行该等义务。within fourteen (14) days of complying with its obligations under clause 3.6(A), certify in writing to the Disclosing Party that the Receiving Party has fully complied with those obligations.各方同意，披露方提供保密信息以及就业务目的进行任何讨论，均不得以默示或其他方式解释为任何一方就订立任何进一步的协议做出任何承诺，或使任何一方负有义务就保密信息、业务目的或其他事项采取、持续采取或停止采取任何行动。The Parties agree that the Disclosing Party’s provision of Confidential Information and any discussions held in connection with the Business Purpose shall not be construed by implication or otherwise as representing any commitment by either Party to enter into any further agreement or oblige any Party to take, continue or forego any action relating to the Confidential Information, the Business Purpose or otherwise.接收方不得倒序制作、反向编译、反向汇编、以化学方法分析、修改或创设基于披露方以有形形式提供的任何保密信息的衍生作品，包括但不限于任何产品、样品、产品原型、电子媒介、合成物或设备。The Receiving party shall not reverse engineer, decompile, disassemble, chemically analyze, modify or create derivative works based on any Confidential Information provided by the Disclosing Party in tangible form, including without limitation, any product, sample, prototype, electronic media, composition or equipment.竞争性行为/Competitive Programs在适用于本协议的情况下，ABC确认并同意，阿斯利康及其关联方：（a）所进行的研发、生产和营销等活动与ABC的业务可能存在竞争关系（“竞争性行为”）；（b）生产、营销、出售、分销或开发的产品及合成物可能与ABC的业务所涉的产品及合成物存在竞争关系（“竞争性产品”）；且（c）现在拥有或以后可能独立开发与ABC向阿斯利康所披露信息类似的信息和其他资料（“类似信息”）。本协议中的任何规定均不得解释为排除阿斯利康及其关联方从事以下行为：（i）从事竞争性行为；（ii）生产、营销、出售、分销或开发竞争性产品；或（iii）使用或以任何方式利用类似信息。Insofar as applicable to this Agreement, ITSC acknowledges and agrees that AstraZeneca and its Affiliates (a) conduct research, development, manufacturing and marketing programs and businesses that may be competitive with ITSC's business (the “Competitive Programs”), (b) manufacture, market, sell and distribute, and may develop, products and compounds that may be competitive with products and compounds related to ITSC's business (the “Competitive Products”), and (c) now possess or may independently develop information and other materials that are similar to the Confidential Information disclosed by ITSC to AstraZeneca (the “Similar Information”). Nothing in this Agreement shall be construed to preclude AstraZeneca and its Affiliates from (i) conducting the Competitive Programs, (ii) manufacturing, marketing, selling, distributing or developing the Competitive Products, or (iii) using or in any way exploiting the Similar Information.陈述与保证/REPRESENTATIONS AND WARRANTIES每一方在此向另一方做出以下陈述与保证：Each Party hereby represents and warrants to the other that:其获得订立本协议的正式授权；it is duly authorised to enter into this Agreement;其目前获得并将继续拥有和遵守对订立和履行本协议所需的所有同意、批准和许可；及it has and will maintain and comply with all consents, approvals and licences necessary for it to enter into and perform this Agreement; and其订立和履行本协议，现在没有、将来亦不会与其任何其他约定义务或任何适用法律和条例相冲突。its entry into and performance of this Agreement does not and will not conflict with any of its other contractual obligations or with any Applicable Laws and Regulations.无许可使用或信赖/NO LICENCE OR RELIANCE本协议中的任何规定均不得默认为或其他方式解释为，明示或默示向接收方授予与保密信息、源自保密信息的任何产品或工序有关的许可使用权或其中任何其他权利，或在本协议订立日之前或之后构思或获取的任何与保密信息有关的发明、发现或改进的相关许可使权或其中任何其他权利。Nothing contained in this Agreement shall be construed, by implication or otherwise, as expressly or impliedly granting to the Receiving Party a licence or any other right in the Confidential Information, or in any products or processes derived therefrom, or in any invention, discovery or improvement relating to such Confidential Information conceived or acquired prior to or after the date of this Agreement.除本协议另有明示规定外，任何一方均不就其保密信息（包括该等保密信息的准确性、完整性）做出任何保证或陈述；任何与该等保密信息有关的暗示的陈述、保证、条款或条件在此均予以排除。Except as expressly stated in this Agreement, neither Party makes any warranty or representation concerning its Confidential Information, including as to its accuracy or completeness and any implied representation, warrants, term or condition related to such Confidential Information is hereby excluded.本协议中的任何规定均不排除或限制任何一方因欺诈或欺诈性不实陈述而应承担的责任。Nothing in this Agreement shall exclude or limit liability for fraud or fraudulent misrepresentation.继续有效/SURVIVAL本协议项下的义务在本协议生效日至有效期届满前持续有效，并且，对于披露方的商业秘密而言，该等保密义务应持续有效直至该等信息不再构成披露方的商业秘密。根据第3.6条归还或销毁保密信息的行为不影响本协议所规定的保密义务。The obligations under this Agreement shall survive its termination or expiry and the termination or the completion of the Business Purpose. The return or destruction of the Confidential Information in accordance with clause 3.6 shall not affect the confidentiality obligations set out in this Agreement.转让和关联方/ASSIGNMENT AND AFFILIATES未经一方事先书面同意，另一方不得全部或部分转让本协议，但阿斯利康可向其任何关联方或本协议所涉所有或绝大部分业务的权益继受人，转让本协议以及本协议项下的权利和义务，无需另一方同意。This Agreement may not be assigned by either Party in whole or in part without the prior written consent of the other Party, except that AstraZeneca may assign this Agreement and its rights and obligations hereunder to any of its Affiliates or any successor in interest to all or substantially all of the business to which this Agreement relates without such consent. 反腐败法/ANTI-CORRUPTION LAWSABC应确保其本身或其任何关联机构，管理人员，雇员，董事，顾问，代理，代表或分包商不应（i）采取任何行动引致任何阿斯利康集团的所属公司可能因违反下述法律而承担法律责任，该等法律包括但不限于：美国1977年海外反腐败法、英国2010年贿赂法令或任何为防止欺诈、贪污、诈骗、洗钱和/或恐怖主义而适用的法律法规；或(ii)导致任何阿斯利康集团所属公司雇员违反行为守则。The ITSC shall ensure that neither it nor any of its Affiliates, officers, employees, directors, consultants, agents, representatives or sub-contractors shall (i) take any action which could render any AstraZeneca group company liable under the US Foreign Corrupt Practices Act of 1977, the UK Bribery Act 2010 or any other Applicable Laws and Regulations for the prevention of fraud, corruption, racketeering, money laundering and/or terrorism or (ii) cause any employee of an AstraZeneca group company to be in violation of the Code of Conduct.一般规定/GENERAL PROVISIONS修改/Variations任何对本协议的修正或更改必须以书面形式并由双方的授权代表签字。Any amendment or modification of this Agreement must be in writing and signed by authorised representatives of both Parties.协议的整体性/Entire Agreement本协议及协议中提到的任何文件组成了双方对于该等事项的完整的协议。本协议取代所有关于该等事项先前的安排、承诺、谅解或协议，无论是书面或口头。双方确认在订立本协议时除本协议另行明确声明外，并不依赖于任何陈述、声明、保证或契约（无论是否来自一方）。一方放弃除本条外的任何陈述、保证、抵押合同或其他保证。任何本协议提到的时间表和附件旨在纳入并在此纳入本协议，成为本协议的一部分。本9.2条不应排除或限制任何由欺诈或欺诈性错误陈述而产生的责任。This Agreement and any documents referred to in it constitute the entire agreement between the Parties with respect to its subject matter. This Agreement supersedes all prior arrangements, undertakings, understandings or agreements, whether written or oral, with respect to its subject matter. Each Party confirms that in entering into this Agreement it is not relying on any statements, representations, warranties or covenants of any person (whether a Party or not) except as specifically set out in this Agreement. Each Party waives all rights and remedies which, but for this clause, might otherwise be available to it in respect of any such representation, warranty, collateral contract or other assurance. All Schedules and Exhibits referred to in this Agreement are intended to be and are hereby specifically incorporated into and made a part of this Agreement. This clause 9.2 shall not exclude or limit liability for fraud or fraudulent misrepresentation.费用/Expenses除非本协议另有说明，双方各自应支付律师或其他专家的费用及开支，以及其他在本协议谈判、准备、执行和送达过程中所产生的全部开支和成本。Except as otherwise expressly provided in this Agreement, each Party shall pay the fees and expenses of its lawyers and other experts and all other expenses and costs incurred by such Party in the negotiation, preparation, execution and delivery of this Agreement.不可抗力/Force Majeure因不可抗力事件导致一方的履行延迟或不履行，该方在不可抗力事件影响范围内不应承担责任。“不可抗力”是指不履约方所无法合理控制的事件，包括天灾，罢工，停工或其他工业/劳资纠纷，战争，暴动，内乱，恐怖行为，恶意破坏，流行病，封锁隔离，火灾，洪水，风暴或自然灾害。此遭受到不可抗力的一方应在事件发生后的五（5）天内立即以书面形式通知另一方上述情况，说明不可抗力的性质、预期的持续时间、任何为避免或减少其影响而采取的行动。任何对履行的暂停不得超过合理的时间和范围。遭受不可抗力的一方应尽力在不产生任何重大开支的情况下弥补其无法履行的责任。如果暂停履行持续六十（60）日且该不履行在没有遭受不可抗力事件的情况下构成对本协议的重大违约，双方应真诚地对本协议的任何修改进行讨论以允许另一方行使其本协议项下的权利。如果双方在三十（30）内无法就该修正案达成协议并且如果暂停履行仍然继续，另一方可立即通过书面方式通知遭受到不可抗力的一方终止本协议，在此情况下，双方除终止日前累计产生的权利和责任外，均不承担其他任何责任。No liability shall result from any delay in performance or non-performance by either Party to this Agreement to the extent caused by an event of Force Majeure. "Force Majeure" means an event that is beyond a non-performing Party's reasonable control, including acts of God, strikes, lock-outs or other industrial/labour disputes, war, riot, civil commotion, terrorist act, malicious damage, epidemics, quarantines, fire, flood, storm or natural disaster. The Party hindered by Force Majeure shall, within five (5) days of its occurrence, give written notice to the other Party stating the nature of the event of Force Majeure, its anticipated duration and any action being taken to avoid or minimize its effect. Any suspension of performance shall be of no greater scope and of no longer duration than is reasonably required and the Force Majeure Party shall use best endeavours without being obligated to incur any material expenditure to remedy its inability to perform; provided, however, if the suspension of performance continues for sixty (60) days and such failure to perform would constitute a material breach of this Agreement in the absence of such event of Force Majeure, the Parties shall meet and discuss in good faith any amendments to this Agreement to permit the other Party to exercise its rights under this Agreement. If the Parties are not able to agree on such amendments within 30 (thirty) days and if suspension of performance continues, such other Party may terminate this Agreement immediately by written notice to the Force Majeure Party, in which case neither Party shall have any liability to the other except for those rights and liabilities that accrued prior to the date of termination.适用法律和争端解决/Governing Law and Dispute Resolution本协议的诠释和解释应适用中华人民共和国法律。除本协议第9.5条另有规定外，因本协议、对本协议的违反、本协议的终止或无效所产生的或与之有关的任何争端、争议或索赔（“争端”），将提交中国国际经济贸易仲裁委员会（“CIETAC”）根据CIETAC仲裁规则在上海以仲裁方式解决。仲裁裁决具有终局性并对双方均有约束力。仲裁程序（包括仲裁结果）均应当保密。The interpretation and construction of this Agreement shall be governed by the laws of People’s Republic of China. Except as otherwise provided in this clause ?9.5, any dispute, controversy or claim arising out of or in connection with this Agreement or the breach, termination or invalidity thereof ("Dispute"), will be submitted to China International Economic and Trade Arbitration Committee (“CIETAC”) for arbitration at Shanghai. The arbitration will be conducted in accordance with the arbitration rules of CIETAC in order to settle the dispute. The arbitral award shall be final and binding upon the Parties. The proceedings, including any outcome, shall be confidential. 双方应将争议上报至管理层以努力解决争议，但该向措施不妨碍一方根据本10.5条款采取任何行动。The Parties shall endeavour to resolve any Dispute by escalation to their management provided that this shall not prevent a Party taking any action under this clause 9.5.本协议第9.5条应不妨碍一方在仲裁前或仲裁中向任何有管辖权的法院申请临时措施、临时救济或保全措施、救济或补救措施，包括临时限制令、预先禁令及其他有关争议的必要的临时救济措施，以在仲裁之前或期间保护该协议方的利益或维持现状。Clause ?9.5 shall not prejudice a Party’s right to apply, either prior to or during any arbitration, to any court of competent jurisdiction for interim, provisional or conservatory measures, relief or remedies, including a temporary restraining order, preliminary injunction or other interim relief, concerning a dispute if necessary to protect the interests of such Party or to preserve the status quo pending the arbitration proceeding. 违约方对于第3.2、3.4、3.6、1或8条的违反将导致非违约方无法挽回的损害并且该损害将无法以现金形式予以充分地赔偿。

　因违反或预期违反于第3.2、3.4、3.6、1或8条而根据本9.5 （D）提起的任何程序，非违约方不应被要求证明无法挽回的损害或损害赔偿不足，或提供任何交叉赔偿承诺、或被要求为该等程序的费用提供担保金或任何形式的担保。A breach by either Party of clauses 3.2, 3.4, 3.6, 1 or 8 will cause irreparable damage to the non-breaching Party and the non-breaching Party will not be adequately compensated by monetary damages. In the event of any proceedings brought pursuant to clause 9.5(D) arising out of a breach, or threatened breach, of clauses 3.2, 3.4, 3.6, 1 or 8, the non-breaching Party shall not be required to prove irreparable injury or the inadequacy of damages or to give any cross undertaking in damages, post a bond or provide any form of security for costs.第三方不得益/No Benefit to Others阿斯利康的关联企业有权执行本协议。This Agreement may be enforced by any Affiliate of AstraZeneca.除本9.6 (A)另有规定外，非协议方无权根据任何适用法律或法规行使本协议项下任何条款。Except as provided in clause ?9.6(A), a Person who is not a Party shall not have any right under Applicable Laws or Regulations or otherwise to enforce any term of this Agreement.双方终止、撤销、同意修改、放弃或和解本协议的权利不以任何非协议方的同意为条件。The right of the Parties to terminate, rescind or agree any variation of or waiver or settlement under this Agreement is not subject to the consent of any Person that is not a Party.通知/Notices任何通知、要求及本协议要求的其他沟通都必须以书面文件形式呈现，且应当说明该等书面文件是与本协议相关的。送达方式应当为专人送达，或由公认的邮递公司以预先支付邮费、隔夜送达的方式或由传真（附传送确认证明）的方式送至双方的下述地址或根据第9.7条另行通知的其他地址。Any notice, request, or other communication required under this Agreement shall be in writing, shall refer specifically to this Agreement, and shall be hand delivered, sent by a recognized overnight delivery service, costs prepaid, or sent by facsimile (with transmission confirmed), addressed to the Parties at their respective addresses above or such other addresses notified in accordance with this clause ?9.7. 双方应不时通知另一方传真号码以便送达。在无另行通时，使用以下传真号码：Each Party shall from time to time notify each other of the facsimile numbers to use for such purposes, and in the absence of